HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

B7-2 expression above a threshold elicits anti-tumor immunity as effective as interleukin-12 and prolongs survival in murine B-cell lymphoma.

Abstract
The costimulatory molecule, B7-2, is expressed by various lymphomas, but this level of expression is not sufficient to generate effective anti-tumor immunity in vivo. To determine whether up-regulated expression of the costimulatory molecule, B7-2, leads to more effective anti-tumor immunity in vivo, the A20 murine model of B-cell lymphoma was used. A20 tumor cells express major histocompatibility complex (MHC) I and II molecules and moderate constitutive levels of B7-2. While B7-1 and B7-2 have been introduced into tumor cells lacking these molecules, studies have not been conducted to determine whether tumors that constitutively express B7-1 or B7-2 can be made more immunogenic by increasing the expression of these molecules. In this report, A20/B7-2 transfectants expressing greater levels of B7-2 were rejected in syngeneic mice, and systemic immunity against the A20 parental cells was generated. Treatment with the A20/B7-2 variant cells significantly improved the survival of tumor-bearing mice. Coinjection with IL-12 secreting variants did not further augment the anti-tumor immunity observed for B7-2 therapy alone. Both CD8(+) T cells and natural killer (NK) cells mediated the anti-tumor immune response observed in A20/B7-2 immunized mice. In mice that developed tumors after immunization with the A20/B7-2 variant cells, resected tumor cells were shown to express lower levels of B7-2 than the transfected variants. These results suggest that the level of costimulation is important for the generation of anti-tumor immunity and for host survival. In addition, tumors appear to be able to evade the immune response by downregulating the expression of B7-2 below a threshold level.
AuthorsEva Pizzoferrato
JournalInternational journal of cancer (Int J Cancer) Vol. 110 Issue 1 Pg. 61-9 (May 20 2004) ISSN: 0020-7136 [Print] United States
PMID15054869 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright 2004 Wiley-Liss, Inc.
Chemical References
  • Antigens, CD
  • B7-2 Antigen
  • Cd86 protein, mouse
  • Membrane Glycoproteins
  • Interleukin-12
Topics
  • Animals
  • Antigens, CD (physiology)
  • B7-2 Antigen
  • Cell Line, Tumor
  • Cytotoxicity, Immunologic
  • Female
  • Interleukin-12 (physiology)
  • Killer Cells, Natural (immunology)
  • Lymphoma, B-Cell (immunology, mortality)
  • Membrane Glycoproteins (physiology)
  • Mice
  • Mice, Inbred BALB C
  • Mice, Inbred C57BL
  • Survival Rate

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: